Latest Insider Transactions at Tela Bio, Inc. (TELA)
This section provides a real-time view of insider transactions for Tela Bio, Inc. (TELA). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of TELA Bio, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of TELA Bio, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 23
2024
|
Megan Smeykal Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
423
-1.41%
|
$2,961
$7.07 P/Share
|
|
Feb 21
2024
|
Megan Smeykal Chief Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
9,400
+23.82%
|
-
|
|
Feb 21
2024
|
Megan Smeykal Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
795
-3.71%
|
$5,565
$7.0 P/Share
|
|
Feb 21
2024
|
Gregory A. Firestone Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
364
-0.99%
|
$2,548
$7.0 P/Share
|
|
Dec 05
2023
|
Gregory A. Firestone Chief Commercial Officer |
BUY
Open market or private purchase
|
Direct |
2,600
+6.82%
|
$13,000
$5.65 P/Share
|
|
Nov 14
2023
|
Roberto Cuca COO and CFO |
BUY
Open market or private purchase
|
Direct |
10,000
+13.82%
|
$40,000
$4.49 P/Share
|
|
Nov 14
2023
|
Antony Koblish Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
11,000
+3.5%
|
$44,000
$4.54 P/Share
|
|
Aug 03
2023
|
Gregory A. Firestone Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
17,950
+35.29%
|
-
|
|
Jun 01
2023
|
Vincent J Burgess Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,135
+21.98%
|
-
|
|
Jun 01
2023
|
John Nosenzo Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,135
+33.33%
|
-
|
|
Jun 01
2023
|
Kurt Azarbarzin Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,135
+33.33%
|
-
|
|
Jun 01
2023
|
Douglas G Evans Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,135
+33.33%
|
-
|
|
Jun 01
2023
|
Lisa N Colleran Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,135
+33.33%
|
-
|
|
Jun 01
2023
|
Federica F. O'Brien Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,135
+33.33%
|
-
|
|
Apr 21
2023
|
Orbimed Advisors LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
27,700
-0.97%
|
$249,300
$9.41 P/Share
|
|
Apr 20
2023
|
Orbimed Advisors LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
28,300
-0.98%
|
$254,700
$9.43 P/Share
|
|
Apr 19
2023
|
Orbimed Advisors LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
136,000
-4.49%
|
$1,224,000
$9.3 P/Share
|
|
Mar 31
2023
|
Paul Talmo Chief Technology Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
187
-0.33%
|
$1,870
$10.64 P/Share
|
|
Mar 31
2023
|
Peter C. Murphy Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
163
-0.43%
|
$1,630
$10.64 P/Share
|
|
Mar 31
2023
|
Megan Smeykal Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
96
-0.47%
|
$960
$10.64 P/Share
|
|
Mar 31
2023
|
Antony Koblish Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
385
-0.13%
|
$3,850
$10.64 P/Share
|
|
Mar 29
2023
|
Vincent J Burgess Director |
BUY
Exercise of conversion of derivative security
|
Direct |
4,860
+37.81%
|
$19,440
$4.44 P/Share
|
|
Feb 24
2023
|
Antony Koblish Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
6,034
-2.02%
|
$66,374
$11.03 P/Share
|
|
Feb 24
2023
|
Paul Talmo Chief Technology Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,032
-1.8%
|
$11,352
$11.03 P/Share
|
|
Feb 24
2023
|
Peter C. Murphy Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
940
-2.4%
|
$10,340
$11.03 P/Share
|
|
Feb 24
2023
|
Megan Smeykal Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
539
-2.56%
|
$5,929
$11.03 P/Share
|
|
Feb 23
2023
|
Roberto Cuca COO and CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
1,300
-2.47%
|
$13,000
$10.5 P/Share
|
|
Feb 23
2023
|
Roberto Cuca COO and CFO |
BUY
Grant, award, or other acquisition
|
Direct |
17,700
+25.18%
|
-
|
|
Feb 23
2023
|
Antony Koblish Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
61,200
+16.99%
|
-
|
|
Feb 23
2023
|
Paul Talmo Chief Technology Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,067
-1.83%
|
$10,670
$10.5 P/Share
|
|
Feb 23
2023
|
Paul Talmo Chief Technology Officer |
BUY
Grant, award, or other acquisition
|
Direct |
16,800
+22.38%
|
-
|
|
Feb 23
2023
|
Peter C. Murphy Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
906
-2.27%
|
$9,060
$10.5 P/Share
|
|
Feb 23
2023
|
Peter C. Murphy Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
16,800
+29.58%
|
-
|
|
Feb 23
2023
|
Megan Smeykal Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
423
-1.97%
|
$4,230
$10.5 P/Share
|
|
Feb 21
2023
|
Megan Smeykal Chief Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
9,400
+30.43%
|
-
|
|
Nov 03
2022
|
Opaleye Management Inc. |
BUY
Open market or private purchase
|
Indirect |
20,262
+0.98%
|
$141,834
$7.81 P/Share
|
|
Oct 11
2022
|
Opaleye Management Inc. |
BUY
Open market or private purchase
|
Indirect |
16,000
+0.79%
|
$128,000
$8.0 P/Share
|
|
Sep 23
2022
|
Opaleye Management Inc. |
BUY
Open market or private purchase
|
Indirect |
6,804
+0.29%
|
$47,628
$7.99 P/Share
|
|
Sep 19
2022
|
Opaleye Management Inc. |
BUY
Open market or private purchase
|
Indirect |
18,000
+0.85%
|
$144,000
$8.09 P/Share
|
|
Sep 16
2022
|
Opaleye Management Inc. |
BUY
Open market or private purchase
|
Indirect |
2,372
+0.21%
|
$18,976
$8.08 P/Share
|
|
Sep 15
2022
|
Opaleye Management Inc. |
BUY
Open market or private purchase
|
Indirect |
4,158
+0.36%
|
$33,264
$8.1 P/Share
|
|
Aug 17
2022
|
Ew Healthcare Partners Fund 2, L.P. |
BUY
Open market or private purchase
|
Indirect |
500,000
+10.86%
|
$4,000,000
$8.0 P/Share
|
|
Aug 16
2022
|
Opaleye Management Inc. |
BUY
Open market or private purchase
|
Indirect |
320,221
+6.33%
|
$2,561,768
$8.05 P/Share
|
|
Aug 10
2022
|
Opaleye Management Inc. |
BUY
Open market or private purchase
|
Indirect |
11,979
+0.59%
|
$95,832
$8.52 P/Share
|
|
Aug 01
2022
|
Opaleye Management Inc. |
BUY
Open market or private purchase
|
Indirect |
4,979
+0.38%
|
$34,853
$7.96 P/Share
|
|
Jul 22
2022
|
Opaleye Management Inc. |
BUY
Open market or private purchase
|
Indirect |
5,200
+0.26%
|
$41,600
$8.02 P/Share
|
|
Jul 21
2022
|
Opaleye Management Inc. |
BUY
Open market or private purchase
|
Indirect |
10,333
+0.72%
|
$82,664
$8.06 P/Share
|
|
Jul 20
2022
|
Opaleye Management Inc. |
BUY
Open market or private purchase
|
Indirect |
5,100
+0.45%
|
$40,800
$8.08 P/Share
|
|
Jul 14
2022
|
Ew Healthcare Partners Fund 2, L.P. |
BUY
Open market or private purchase
|
Indirect |
5,000
+0.14%
|
$40,000
$8.01 P/Share
|
|
Jul 13
2022
|
Ew Healthcare Partners Fund 2, L.P. |
BUY
Open market or private purchase
|
Indirect |
5,000
+0.14%
|
$40,000
$8.03 P/Share
|